{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:04:23Z","timestamp":1771437863888,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04220-x","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:54:48Z","timestamp":1769176488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD56 negativity is associated with worse survival outcomes in patients with multiple myeloma: a meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Guiyang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenchao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"1","key":"4220_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45.","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 2","key":"4220_CR2","doi-asserted-by":"publisher","first-page":"e70067","DOI":"10.1002\/hon.70067","volume":"43","author":"F Gay","year":"2025","unstructured":"Gay F, Marchetti E, Bertuglia G. Multiple myeloma unpacked. Hematol Oncol. 2025;43(Suppl 2):e70067.","journal-title":"Hematol Oncol"},{"issue":"9","key":"4220_CR3","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324.","journal-title":"Am J Hematol"},{"issue":"24","key":"4220_CR4","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International myeloma Society\/International myeloma working group consensus recommendations on the definition of High-Risk multiple myeloma. J Clin Oncology: Official J Am Soc Clin Oncol. 2025;43(24):2739\u201351.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4220_CR5","doi-asserted-by":"crossref","unstructured":"Besliu C, Tanase AD, Rotaru I, Espinoza J, Vidal L, Poelman M, et al. The evolving landscape in multiple myeloma: from risk stratification to T Cell-Directed advanced therapies. Cancers. 2025;17(3):525.","DOI":"10.3390\/cancers17030525"},{"issue":"2","key":"4220_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100\u201313.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10272","key":"4220_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet (London England). 2021;397(10272):410\u201327.","journal-title":"Lancet (London England)"},{"issue":"1","key":"4220_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-019-0750-5","volume":"12","author":"D Hose","year":"2019","unstructured":"Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, et al. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. J Hematol Oncol. 2019;12(1):65.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"4220_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ajh.25415","volume":"94","author":"R Chakraborty","year":"2019","unstructured":"Chakraborty R, Liu HD, Rybicki L, Tomer J, Khouri J, Dean RM, et al. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. Am J Hematol. 2019;94(4):439\u201345.","journal-title":"Am J Hematol"},{"issue":"4","key":"4220_CR10","first-page":"1071","volume":"24","author":"Q Qiu","year":"2016","unstructured":"Qiu Q, Zhu P, Wang MJ, Lu XZ, Dong YJ, Sun YH, et al. Expression of CD56 and CD19 in patients with newly diagnosed multiple myeloma and their relationship with karyotypes and prognosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(4):1071\u20138.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"4","key":"4220_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000489483","volume":"139","author":"M Skerget","year":"2018","unstructured":"Skerget M, Skopec B, Zadnik V, Zontar D, Podgornik H, Rebersek K, et al. CD56 expression is an important prognostic factor in multiple myeloma even with bortezomib induction. Acta Haematol. 2018;139(4):228\u201334.","journal-title":"Acta Haematol"},{"issue":"5","key":"4220_CR12","first-page":"5655","volume":"16","author":"H Wang","year":"2018","unstructured":"Wang H, Zhou X, Zhu JW, Ye JN, Guo HF, Sun C. Association of CD117 and HLA-DR expression with shorter overall survival and\/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation. Oncol Lett. 2018;16(5):5655\u201366.","journal-title":"Oncol Lett"},{"issue":"11","key":"4220_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-020-01423-4","volume":"37","author":"M Okura","year":"2020","unstructured":"Okura M, Ida N, Yamauchi T. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era. Med Oncol. 2020;37(11):103.","journal-title":"Med Oncol"},{"issue":"1","key":"4220_CR14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1186\/s12885-022-10382-0","volume":"22","author":"C Geng","year":"2022","unstructured":"Geng C, Zhou H, Wang H, Li Y, Leng Y, Zhang Z, et al. Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation. BMC Cancer. 2022;22(1):1349.","journal-title":"BMC Cancer"},{"key":"4220_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"4220_CR16","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomiazed studies in meta-analysis [Internet]. 2023 [cited February 20, 2023]. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm."},{"issue":"4","key":"4220_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/aogs.14712","volume":"103","author":"S Folkins","year":"2024","unstructured":"Folkins S, Miller A, Nash CM. Risk of venous thromboembolism in pregnant patients with active malignancy: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2024;103(4):645\u201352.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"4220_CR18","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1046\/j.1365-2141.2002.03513.x","volume":"117","author":"N Sahara","year":"2002","unstructured":"Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117(4):882\u20135.","journal-title":"Br J Haematol"},{"issue":"1","key":"4220_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/10428190500272549","volume":"47","author":"H Chang","year":"2006","unstructured":"Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma. 2006;47(1):43\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"4220_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/sj.bmt.1705857","volume":"40","author":"M Hundemer","year":"2007","unstructured":"Hundemer M, Klein U, Hose D, Raab MS, Cremer FW, Jauch A, et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transpl. 2007;40(11):1033\u20137.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"4220_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/10428190701760532","volume":"49","author":"M Kraj","year":"2008","unstructured":"Kraj M, Soko\u0142owska U, Kope\u0107-Szlezak J, Pog\u0142\u00f3d R, Kruk B, Wo\u017aniak J, et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma. 2008;49(2):298\u2013305.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"4220_CR22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/jcp.2009.065128","volume":"62","author":"NT Ngo","year":"2009","unstructured":"Ngo NT, Brodie C, Giles C, Horncastle D, Klammer M, Lampert IA, et al. The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome. J Clin Pathol. 2009;62(11):1009\u201315.","journal-title":"J Clin Pathol"},{"key":"4220_CR23","unstructured":"Miyazaki K, Suzuki KJIJM. Clinical and laboratory significance of CD56 (a neural cell adhesion molecule) positivity in multiple myeloma and AL amyloidosis. Int J Myelom. 2015;5(3):30\u20135."},{"key":"4220_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.leukres.2015.11.003","volume":"40","author":"Y Pan","year":"2016","unstructured":"Pan Y, Wang H, Tao Q, Zhang C, Yang D, Qin H, et al. Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Res. 2016;40:77\u201382.","journal-title":"Leuk Res"},{"key":"4220_CR25","unstructured":"Fan QY, Wang Y, Mi JQJJSJU. Study on the efficacy of bortezomib on CD56 negative multiple myeloma patients. J Shanghai Jiaotong Univ. 2016;36(10):1445\u201350."},{"issue":"5","key":"4220_CR26","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.3892\/ol.2017.5920","volume":"13","author":"N Iriyama","year":"2017","unstructured":"Iriyama N, Miura K, Hatta Y, Kobayashi S, Uchino Y, Kurita D, et al. Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncol Lett. 2017;13(5):3803\u201308.","journal-title":"Oncol Lett"},{"issue":"8","key":"4220_CR27","first-page":"693","volume":"40","author":"J Shi","year":"2019","unstructured":"Shi J, Sun K, Zhu ZM, Lei PC, Liu ZW, Chen YQ, et al. Prognostic significance of CD56 and CD117 expression in patients with newly diagnosed multiple myeloma treated with bortezomib-based first-line therapy. Zhonghua Xue Ye Xue Za Zhi. 2019;40(8):693\u201396.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"4220_CR28","doi-asserted-by":"publisher","first-page":"153567","DOI":"10.1016\/j.prp.2021.153567","volume":"225","author":"E Koumpis","year":"2021","unstructured":"Koumpis E, Tassi I, Malea T, Papathanasiou K, Papakonstantinou I, Serpanou A, et al. CD56 expression in multiple myeloma: correlation with poor prognostic markers but no effect on outcome. Pathol Res Pract. 2021;225:153567.","journal-title":"Pathol Res Pract"},{"issue":"40","key":"4220_CR29","doi-asserted-by":"publisher","first-page":"e30988","DOI":"10.1097\/MD.0000000000030988","volume":"101","author":"L Li","year":"2022","unstructured":"Li L, Li X, Shang A, Zhao Y, Jin L, Zhao M, et al. Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study. Med (Baltim). 2022;101(40):e30988.","journal-title":"Med (Baltim)"},{"key":"4220_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jcm11216524","volume":"11","author":"D Zheng","year":"2022","unstructured":"Zheng D, Zhu M, Li Q, Wan W, Chen Y, Jing H. Dual negativity of CD56 and CD117 links to unfavorable cytogenetic abnormalities and predicts poor prognosis in multiple myeloma. J Clin Med. 2022;11:21.","journal-title":"J Clin Med"},{"issue":"175","key":"4220_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.24976\/Discov.Med.202335175.16","volume":"35","author":"M Li","year":"2023","unstructured":"Li M, Bai Y, Sun X, Wang H, Li W, Xiao X, et al. High red blood cell distribution width to platelet ratio is an independent poor prognostic factor in patients with newly diagnosed multiple myeloma. Discov Med. 2023;35(175):157\u201367.","journal-title":"Discov Med"},{"issue":"3","key":"4220_CR32","first-page":"777","volume":"31","author":"XX Wang","year":"2023","unstructured":"Wang XX, Zhang LL, Wang T, Hou JX, Wang ZT, Qin H. Prognostic value of CD56 expression in newly diagnosed multiple myeloma patients and its related factors. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(3):777\u201382.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"4","key":"4220_CR33","first-page":"236","volume":"41","author":"H Keski","year":"2024","unstructured":"Keski H, Merdan S, Zemheri IE. Evaluation of CD56 and CD117 Double-Positivity as a predictor of poor prognosis in multiple myeloma patients: A retrospective analysis. Turk J Haematol. 2024;41(4):236\u201345.","journal-title":"Turk J Haematol"},{"issue":"4","key":"4220_CR34","doi-asserted-by":"publisher","first-page":"e0320934","DOI":"10.1371\/journal.pone.0320934","volume":"20","author":"SK Rajput","year":"2025","unstructured":"Rajput SK, Minhas K, Azam I, Habib S, Shaikh U, Lalani EN. Prognostic implications of MUC1 and XBP1 concordant expression in multiple myeloma: A retrospective study. PLoS ONE. 2025;20(4):e0320934.","journal-title":"PLoS ONE"},{"issue":"1","key":"4220_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/16078454.2021.2019365","volume":"27","author":"L Zhang","year":"2022","unstructured":"Zhang L, Huang Y, Lin Y, Zhang A, Zou R, Xu H, et al. Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis. Hematology. 2022;27(1):122\u201331.","journal-title":"Hematology"},{"issue":"1","key":"4220_CR36","doi-asserted-by":"publisher","first-page":"8756","DOI":"10.1038\/s41598-019-45377-8","volume":"9","author":"G Taouk","year":"2019","unstructured":"Taouk G, Hussein O, Zekak M, Abouelghar A, Al-Sarraj Y, Abdelalim EM, et al. CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse. Sci Rep. 2019;9(1):8756.","journal-title":"Sci Rep"},{"issue":"2","key":"4220_CR37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/10428190802699332","volume":"50","author":"T Damgaard","year":"2009","unstructured":"Damgaard T, Knudsen LM, Dahl IM, Gimsing P, Lodahl M, Rasmussen T. Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma. Leuk Lymphoma. 2009;50(2):236\u201346.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"4220_CR38","doi-asserted-by":"publisher","first-page":"e0196780","DOI":"10.1371\/journal.pone.0196780","volume":"13","author":"T Yoshida","year":"2018","unstructured":"Yoshida T, Ri M, Kinoshita S, Narita T, Totani H, Ashour R, et al. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma. PLoS ONE. 2018;13(5):e0196780.","journal-title":"PLoS ONE"},{"issue":"1","key":"4220_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-025-01284-y","volume":"15","author":"G Giorgetti","year":"2025","unstructured":"Giorgetti G, Maroto-Martin E, Soncini D, Fenoglio D, Becherini P, Benzi A, et al. CD56 expression modulates NAD\u2009+\u2009metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma. Blood Cancer J. 2025;15(1):83.","journal-title":"Blood Cancer J"},{"key":"4220_CR40","doi-asserted-by":"publisher","unstructured":"Jang SY, Jang J, Lee JS, Seong MW, Park S, Byun JM, et al. Prognostic landscape of TP53 mutations in hematologic malignancies. Cancer Res Treat. 2025. https:\/\/doi.org\/10.4143\/crt.2025.297.","DOI":"10.4143\/crt.2025.297"},{"issue":"3","key":"4220_CR41","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1365-2141.2011.08849.x","volume":"155","author":"SJ Jacobus","year":"2011","unstructured":"Jacobus SJ, Kumar S, Uno H, Van Wier SA, Ahmann GJ, Henderson KJ, et al. Impact of high-risk classification by FISH: an Eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol. 2011;155(3):340\u20138.","journal-title":"Br J Haematol"},{"issue":"7","key":"4220_CR42","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajh.23731","volume":"89","author":"K Kim","year":"2014","unstructured":"Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical profiles of multiple myeloma in Asia-An Asian myeloma network study. Am J Hematol. 2014;89(7):751\u20136.","journal-title":"Am J Hematol"},{"issue":"1","key":"4220_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12920-025-02116-5","volume":"18","author":"X Chen","year":"2025","unstructured":"Chen X, Luo T, Zhang W, Wang S, Zhu M, He H, et al. Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients. BMC Med Genom. 2025;18(1):50.","journal-title":"BMC Med Genom"},{"key":"4220_CR44","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol. 2023;14:1101495.","journal-title":"Front Immunol"},{"issue":"1","key":"4220_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z, Xu X, Liu H, Zhao X, Yang C, Fu R. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol. 2023;12(1):99.","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"4220_CR46","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk N, Leleu X, G\u00e1llego P\u00e9rez-Larraya J, et al. International myeloma working group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25(5):e205\u201316.","journal-title":"Lancet Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04220-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04220-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04220-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:05:08Z","timestamp":1771434308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04220-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4220"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04220-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}